Avicanna Inc. (TSX:AVCN)

Market Cap	26.29M
Revenue (ttm)	25.46M
Net Income (ttm)	-3.62M
Shares Out	111.86M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	92,647
Average Volume	246,282
Open	0.2350
Previous Close	0.2350
Day's Range	0.2300 - 0.2350
52-Week Range	0.2000 - 0.5500
Beta	0.27
RSI	43.85
Earnings Date	May 9, 2025

About Avicanna

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. It commercializes approximately thirty proprietary evidence-based finished products. The company provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 87
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: AVCN

Financial Performance

In 2024, Avicanna's revenue was 25.46 million, an increase of 51.62% compared to the previous year's 16.79 million. Losses were -3.62 million, -58.62% less than in 2023.